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Introduction
Clostridium difficile is an anaerobic, spore forming Gram 
positive bacillus which is a worldwide enteric pathogen. 
It is a common cause of  antibiotic associated diarrhoea 
and colitis and was identified as the cause of  antibiotic 
associated pseudomembranous colitis in the late 1970s.  
Since 2000, C. difficile infection (CDI) has had a higher 
profile following reports of  increasing rates, mortality 
and morbidity, and outbreaks have presented significant 
challenges to many healthcare facilities.  CDI was initially 
associated with hospital acquired infection but community 
acquired infections are being increasingly recognised.  
Most of  the literature surrounding CDI epidemiology 
relates to the disease in developed countries but it seems 
unlikely that this pathogen will not have the potential to 
cause problems in developing countries like South Sudan, 
particularly on a background of  unregulated antibiotic 
use.   
Pathogenesis
Colonization with C. difficile occurs following disruption 
of  the normal intestinal flora which usually provides 
resistance to such colonization, particularly following 
antibiotic use.  C. difficile is acquired by the faecal-oral 
route; the bacterial spores are not destroyed by gastric 
acid, enabling them to reach the intestines.  
The development of  active CDI requires toxin production. 
There are two main toxins (A and B) produced by C. 
difficile, both of  which can cause symptomatic disease 
independently of  each other.  The toxins disrupt the 
cytoskeleton of  the intestinal mucosal cells, leading to 
intestinal fluid secretion, damage of  the intestinal mucosa 
and inflammation.  
There are many different strains of  C. difficile and certain 
strains are associated with higher virulence, particularly 
the North American type 1 (NAP1)/027 ribotype, first 
reported in 2003 from Canada [1], which has been 
linked to more symptomatic disease and more severe 
presentations.  
Epidemiology
C. difficile has been isolated globally from environmental 
sources both in and outside the hospital.   Although most 
of  the research comes from industrialized countries, one 
study in rural Zimbabwe found toxigenic C. difficile  in 
samples of  soil, chicken faeces and water [2], highlighting 
the potential for acquisition of  the organism in Africa.  
Asymptomatic colonisation is common in children, 
reported in up to 70% of  healthy neonates [3], compared 
to around 3% of  healthy adults and 20% of  hospitalized 
adults [4].  Some studies have indicated geographical 
variation in C. difficile colonization and infection rates, with 
some suggesting that the risk in Africa is lower.  One study 
comparing HIV positive adults with diarrhoea in London, 
UK and Lusaka, Zambia found no patients with CDI in 
Lusaka, compared to 11% in London [5].  However, C. 
difficile colonisation was detected in 48.8% of  Nigerian 
neonates and children in an earlier study [6],  and another 
more recent Nigerian study of  HIV positive patients with 
diarrhoea demonstrated CDI in 14% of  outpatients and 
43.5% of  inpatients [7].  
The major risk factor for developing C. difficile infection is 
receiving antibiotic therapy. Broader spectrum antibiotics 
are associated with a higher risk of  C. difficile, causing 
Figure 1.  Pseudomembranous colitis at colonoscopy with multiple 
yellowish patches (“pseudomembranes”) and erythematous, 
friable mucosa. (From Limaye et al, 2000].
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more disruption of  the intestinal flora.  The “four Cs” 
are a particular risk:  clindamycin, ciprofloxacin (and other 
quinolones), cephalosporins and co-amoxiclav.  A higher 
number of  antimicrobial agents, doses and duration are all 
associated with increased CDI risk [8].
The current lack of  publications demonstrating a 
significant CDI problem in many African countries is 
likely to reflect a lack of  detection and reporting rather 
than a lack of  risk, given that the organism is present in 
the continent and antibiotic use in many African countries 
is high, with uncontrolled over the counter access without 
prescription.  
Age, co-morbidities, including malignancy and chronic 
renal disease, and other medications such as chemotherapy 
agents are also recognised factors increasing the risk of  
CDI.  HIV infection by itself  is not thought to increase 
the risk of  CDI, although these patients are more likely to 
receive antibiotics leading to an increased CDI risk [4].  
Presentation
Although many remain asymptomatic with C. difficile 
colonisation, toxin production results in presentations 
ranging from mild, transient diarrhoea to severe diarrhoea 
with a pseudomembranous colitis (Figure 1) which 
can be fatal.  Abdominal pain and non-specific signs 
may be present, including fever, nausea, anorexia and 
dehydration.  
Occasionally, severe disease can present without 
diarrhoea, with an acute abdomen, peritonitis or toxic 
megacolon (dilatation of  the colon to greater than 6cm 
without obstruction with systemic signs of  toxicity) which 
is associated with a high mortality rate. 
 Recurrences are common, occurring in around 20% of  
patients, and complications include perforation of  the 
colon, transverse colonic volvulus and protein losing 
enteropathy. Extra-intestinal manifestations of  CDI are 
rare.  
Diagnosis of C. difficile
CDI diagnosis involves detecting the organism and its 
toxin production from diarrhoeal specimens.  
One common testing strategy uses a two step algorithm 
in which an enzyme immune-assay (EIA) for glutamate 
dehydrogenase (GDH) , an enzyme with a high sensitivity 
for the presence of  C. difficile, is performed first, followed 
by a C. difficile toxin EIA in the GDH positive samples 
[9).  In resource limited settings, such as South Sudan, use 
of  the toxin EIA alone may be more appropriate given 
the rapid turn around and reagent availability.  Other 
techniques include culture, tissue culture cytotoxicity 
testing and toxin gene detection by polymerase chain 
reaction.  
Treatment 
Treating CDI involves firstly stopping any non-essential 
systemic antibiotics and secondly using a specific agent 
against C. difficile.  The two agents with most evidence 
for successful treatment of  CDI are metronidazole and 
vancomycin.  Metronidazole is used in non-severe cases 
of  infection and is normally administered orally or can be 
given intravenously if  there is a reason for the oral drug not 
reaching the affected bowel, e.g.  intestinal obstruction.  
Vancomycin is usually used for more severe infections, 
although the new agent fidaxomicin is now being used in 
some centres.  Vancomycin is given orally as intravenous 
vancomycin is not secreted into the intestinal lumen. 
Patients with unresponsive or recurrent disease can be 
difficult to treat and approaches include tapering courses 
of  vancomycin, intravenous immunoglobulin, and donor 
“faecal transplant” therapy, for which there is a growing 
body of  evidence.  
Prevention 
Strategies to prevent CDI include controlling the spread 
of  C. difficile, particularly within healthcare facilities, and 
minimizing antibiotic exposure, thereby avoiding the 
disruption of  colonic flora which leaves the patient at 
risk of  C. difficile colonization.  Preventing the spread 
in hospitals involves side room isolation of  patients 
with suspected or confirmed CDI with barrier nursing, 
effective cleaning of  the patient’s environment and careful 
hand hygiene practices by healthcare workers, with soap 
and water.  
Figure 2: Antimicrobial Usage in Hospital in England 2005-2009, 
Cephalosporins, Quinolones, Carbapenems and Anti-pseudomonal 
penicillins.   (From:  Ashiru-Oredope et al  2012]  
DDDs:  defined daily doses
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CDI reduction has been a key factor in driving the 
development of  antimicrobial stewardship programmes 
around the world, along with increasing antimicrobial 
resistance.  Restricting the use of  antibiotics, both by 
minimizing overall antibiotic consumption and by selecting 
the narrower spectrum lower risk agents is therefore 
an important method in reducing the problem.  In the 
UK, rates of  CDI and mortality from CDI have declined 
significantly, following improvements in infection control 
and increased antibiotic stewardship.  Figure 2 illustrates 
the decrease in England in prescription of  cephalosporins 
and quinolones (high risk antibiotics), which is mirrored 
by a decrease in reported CDI cases over a similar time 
period (Figure 3).  
In summary, CDI is an important cause of  diarrhoea, 
particularly antibiotic associated, which can result in severe 
disease.  Countries without effective control of  antibiotic 
use have a high potential for problems with this organism 
and it should be considered in the differential diagnosis of  
patients with diarrhoea.  
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